Hopital Maisonneuve-Rosemont, centre de recherché
Development of new prognostic markers in acute myeloid leukemia
Acute myeloid leukemia (AML) is a deadly cancer treated with intensive chemotherapy to achieve remission followed by consolidation treatment to prevent relapse. Consolidation with chemotherapy or stem cell transplantation is chosen according to the risk of relapse which is determined by genetic anomalies in leukemia cells. This research aims to identify new prognostic markers to improve the risk stratification of AML patients and help clinicians select the most appropriate treatment.